Rasagiline: a review of its use in the management of Parkinson's disease.

Rasagiline: a review of its use in the management of Parkinson's disease. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Rasagiline: a review of its use in the management of Parkinson's disease. Abstract Text:

Vicki Oldfield,Gillian M Keating,Caroline M Perry,

Rasagiline (Azilect) is a novel, selective, irreversible second-generation inhibitor of monoamine oxidase type B (MAO-B). It is administered orally once daily and is approved in the US, Canada, Mexico, Israel and the EU for use as monotherapy and as adjunct therapy in the treatment of Parkinson's disease.Results of well designed clinical studies indicate that rasagiline is effective as initial monotherapy and improves Parkinson's symptomatology in patients with early Parkinson's disease. In addition, when administered in conjunction with levodopa, in patients with moderate to advanced disease and motor fluctuations, rasagiline reduces mean daily 'off' time and increases daily 'on' time without troublesome dyskinesias, compared with controls. Rasagiline is generally well tolerated as monotherapy and adjunctive therapy and is administered once daily. Thus, rasagiline, administered as a simple and convenient dosage regimen, is a well tolerated and effective option for monotherapy in patients with early Parkinson's disease and for adjunctive therapy in patients with moderate to advanced disease.

Rasagiline: a review of its use in the management of Parkinson's disease. Publishing Authors By Initials

V Oldfield,GM Keating,CM Perry,

For similar nervous system diseases: central nervous system diseases: brain diseases: basal ganglia diseases: parkinsonian disorders: parkinson disease research abstracts see: nervous system diseases: central nervous system diseases: brain diseases: basal ganglia diseases: parkinsonian disorders: parkinson disease research

PUBMED ID PMID:

MEDLINE DATE:

Rasagiline: a review of its use in the management of Parkinson's disease. Journal Published:

PUBLICATION TYPE: Review

Journal: Drugs

VOLUME: 67

Page Numbers: 1725-47

Journal Abbreviation: Drugs

ISSN: 0012-6667

DAY: 27

MONTH: 11

YEAR: 2007

Rasagiline: a review of its use in the management of Parkinson's disease. Information

Number of References: 107

LANGUAGE: eng

NlmUniqueID: 7600076

Rasagiline: a review of its use in the management of Parkinson's disease. Keywords Mesh Terms:

KEYWORDS: Parkinson Disease

MESH TERMS: drug therapy

Chemical & Substance for Abstract: Rasagiline: a review of its use in the management of Parkinson's disease. Information

Substance Name: rasagiline

Registry Number: 1875-50-9

Grant and Affiliation Information for Rasagiline: a review of its use in the management of Parkinson's disease.

AFFILIATION: Wolters Kluwer Health | Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA.

Country: New Zealand

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Drugs

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Rasagiline: a review of its use in the management of Parkinson's disease Related Publications

• "Stay away from them until you're old enough to make a decision": tobacco company testimony about youth smoking initiation.
• 9p21 and 13q14 dosages in ependymomas. A clinicopathologic study of 101 cases.
• A reverse-translational approach to bipolar disorder: rodent and human studies in the Behavioral Pattern Monitor.
• Adults with autism show increased sensitivity to outcomes at low error rates during decision-making.
• Balanced production of ribosomal proteins.
• Bias, benefit, or both: evaluating new glioma therapies.
• Comparison of two methods for measuring tongue pressure during swallowing in people with head and neck cancer.
• Congenital glioblastoma: a clinicopathologic and genetic analysis.
• Constraints on practice.
• Gender identity and adjustment in black, Hispanic, and white preadolescents.
• Glioblastoma.
• Hierarchy of iron uptake systems: Yfu and Yiu are functional in Yersinia pestis.
• Identification of critical amino acid residues in the plague biofilm Hms proteins.
• Lipoic acid and N-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts.
• On-board Imaging - the Ipswich Experience.
• Oxidative damage to RNA in neurodegenerative diseases.
• Power in Numbers: Using EPINet Data to Promote Protective Policies for Healthcare Workers.
• Rasagiline: a review of its use in the management of Parkinson's disease.
• Rectus sheath hematoma: a series of unfortunate events.
• Road effects on abundance and fitness of Galápagos lava lizards (Microlophus albemarlensis).
• Selective loss of dopamine D2 receptors in temporal cortex in dementia with Lewy bodies, association with cognitive decline.
• Selective reporting of pharmaceutical data leads major medical journals to change editorial policy.
• Small cell lung cancer: have we made any progress over the last 25 years?
• Spotlight on ramipril in the prevention of cardiovascular outcomes.
• Tacrolimus once-daily formulation : in the prophylaxis of transplant rejection in renal or liver allograft recipients.
• The relationship between sensorimotor gating and clinical improvement in acutely ill schizophrenia patients.
• Vascular oxidative stress in Alzheimer disease.
• Walking in a city neighbourhood, paving the way.
• Work-related ladder fall fractures: identification and diagnosis validation using narrative text.
• You can make a difference.